Genocea Announces Proposed Public Offering of Common Stock
A registration statement relating to the securities being sold in this offering has been filed with the
The offering is being made only by means of a prospectus, copies of which may be obtained from
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called “inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020.
This press release includes forward-looking statements, including statements relating to the proposed underwritten public offering within the meaning of the Private Securities Litigation Reform Act and the timing for filing of an Investigational New Drug Application for GEN-011. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Applicable risks and uncertainties include those related to market conditions, the final terms of the proposed offering, satisfaction of customary closing conditions related to the public offering and those identified under the heading "Risk Factors" included in the preliminary prospectus related to the proposed offering filed with the
Source: Genocea Biosciences, Inc.